U.S. Department of Health and Human Services
Marc Ghany

 Contact Info

Tel: 301-402-5115
Email: mg228m@nih.gov

 Select Experience

  • Staff ClinicianLDB, NIDDK, NIH2000-present
  • Medical Staff FellowLDB, NIDDK, NIH1996-2000
  • Clinical InstructorDepartment of Medicine, Section of Gastroenterology and Hepatology, Tulane University1995-1996
  • FellowTulane University1992-1995
  • M.H.Sc.Duke University2010
  • M.D.Royal College of Surgeons, Ireland1989

 Related Links



    Marc Ghany, M.D., M.H.Sc.

    Staff Clinician, Liver Diseases BranchClinical Research Section
    • Clinical Research


    A selection of recent and significant publications can be viewed below.

    Ghany MG, Gara N. QUEST for a cure for hepatitis C virus: the end is in sight. Lancet. 2014 Aug 2; 384 (9941):381-3. [Full Text/Abstract]
    Ghany M, Perrillo R, Li R, Belle SH, Janssen HL, Terrault NA, Shuhart MC, Lau DT, Kim WR, Fried MW, Sterling RK, Di Bisceglie AM, Han SH, Ganova-Raeva LM, Chang KM, Lok AS, Hepatitis B Research Network. Characteristics of Adults in the Hepatitis B Research Network in North America Reflect Their Country of Origin and Hepatitis B Virus Genotype. Clin Gastroenterol Hepatol. 2014 Jul 7. [Full Text/Abstract]
    Liang TJ, Ghany MG. Therapy of Hepatitis C - Back to the Future. N Engl J Med. 2014 May 22; 370 (21):2043-7. [Full Text/Abstract]
    Rotman Y, Noureddin M, Feld JJ, Guedj J, Witthaus M, Han H, Park YJ, Park SH, Heller T, Ghany MG, Doo E, Koh C, Abdalla A, Gara N, Sarkar S, Thomas E, Ahlenstiel G, Edlich B, Titerence R, Hogdal L, Rehermann B, Dahari H, Perelson AS, Hoofnagle JH, Liang TJ. Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut. 2014 Jan; 63 (1):161-9. [Full Text/Abstract]
    Werner JM, Abdalla A, Gara N, Ghany MG, Rehermann B. The Hepatitis B Vaccine Protects Re-Exposed Healthcare Workers, but Does Not Provide Sterilizing Immunity. Gastroenterology. 2013 Nov; 145 (5):1026-34. [Full Text/Abstract]
    Noureddin M, Wright EC, Alter H, Clark S, Thomas E, Chen R, Zhao X, Conry-Cantilena C, Kleiner D, Liang TJ, Ghany MG. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: A longitudinal analysis. Hepatology. 2013 Nov; 58 (5):1548-57. [Full Text/Abstract]
    Safar Zadeh E, Lungu AO, Cochran EK, Brown RJ, Ghany MG, Heller T, Kleiner DE, Gorden P. The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol. 2013 Jul; 59 (1):131-7. [Full Text/Abstract]
    Gara N, Ghany MG. What the infectious disease physician needs to know about pegylated interferon and ribavirin. Clin Infect Dis. 2013 Jun; 56 (11):1629-36. [Full Text/Abstract]
    Samala NR, Ghany MG. Acute hepatitis C: to treat or not to treat. Lancet Infect Dis. 2013 Jun; 13 (6):467-8. [Full Text/Abstract]
    Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013 May 16; 368 (20):1907-17. [Full Text/Abstract]
    Gara N, Zhao X, Kleiner DE, Liang TJ, Hoofnagle JH, Ghany MG. Discordance among transient elastography, aspartate aminotransferase to platelet ratio index, and histologic assessments of liver fibrosis in patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2013 Mar; 11 (3):303-8.e1. [Full Text/Abstract]
    Thomas E, Ghany MG, Liang TJ. The application and mechanism of action of ribavirin in therapy of hepatitis C. Antivir Chem Chemother. 2012 Sep 25; 23 (1):1-12. [Full Text/Abstract]
    Pan CQ, Mi LJ, Bunchorntavakul C, Karsdon J, Huang WM, Singhvi G, Ghany MG, Reddy KR. Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. Dig Dis Sci. 2012 Sep; 57 (9):2423-9. [Full Text/Abstract]
    Allison RD, Conry-Cantilena C, Koziol D, Schechterly C, Ness P, Gibble J, Kleiner DE, Ghany MG, Alter HJ. A 25-year study of the clinical and histologic outcomes of hepatitis C virus infection and its modes of transmission in a cohort of initially asymptomatic blood donors. J Infect Dis. 2012 Sep 1; 206 (5):654-61. [Full Text/Abstract]
    Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, Jewett A, Baack B, Rein DB, Patel N, Alter M, Yartel A, Ward JW, Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012 Aug 17; 61 (RR-4):1-32. [Full Text/Abstract]
    Morishima C, Shiffman ML, Dienstag JL, Lindsay KL, Szabo G, Everson GT, Lok AS, Di Bisceglie AM, Ghany MG, Naishadham D, Morgan TR, Wright EC. Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. Am J Gastroenterol. 2012 Jun 12. [Full Text/Abstract]
    Curto TM, Lagier RJ, Lok AS, Everhart JE, Rowland CM, Sninsky JJ, HALT-C Trial group. Predicting cirrhosis and clinical outcomes in patients with advanced chronic hepatitis C with a panel of genetic markers (CRS7). Pharmacogenet Genomics. 2011 Dec; 21 (12):851-60. [Full Text/Abstract]
    Ghany MG, Kim HY, Stoddard A, Wright EC, Seeff LB, Lok AS, HALT-C Trial Group. Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. Hepatology. 2011 Nov; 54 (5):1527-37. [Full Text/Abstract]
    Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB, American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011 Oct; 54 (4):1433-44. [Full Text/Abstract]
    Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C, Stoddard AM, Everhart JE, HALT-C Trial Group. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011 Aug; 54 (2):396-405. [Full Text/Abstract]
    Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR, HALT-C Trial Group. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology. 2011 Aug; 54 (2):434-42. [Full Text/Abstract]
    Abu Dayyeh BK, Yang M, Fuchs BC, Karl DL, Yamada S, Sninsky JJ, O'Brien TR, Dienstag JL, Tanabe KK, Chung RT, HALT-C Trial Group. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology. 2011 Jul; 141 (1):141-9. [Full Text/Abstract]
    Freedman ND, Curto TM, Lindsay KL, Wright EC, Sinha R, Everhart JE, HALT-C TRIAL GROUP. Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. Gastroenterology. 2011 Jun; 140 (7):1961-9. [Full Text/Abstract]
    Lambrecht RW, Sterling RK, Naishadham D, Stoddard AM, Rogers T, Morishima C, Morgan TR, Bonkovsky HL, HALT-C Trial Group. Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology. 2011 May; 140 (5):1490-500.e3. [Full Text/Abstract]
    Fontana RJ, Sanyal AJ, Ghany MG, Bonkovsky HL, Morgan TR, Litman HJ, Reid AE, Lee WM, Naishadham D, HALT-C Trial Study Group. Development and progression of portal hypertensive gastropathy in patients with chronic hepatitis C. Am J Gastroenterol. 2011 May; 106 (5):884-93. [Full Text/Abstract]
    Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, Morishima C, Wright EC, Snow KK, Lee WM, Fontana RJ, Morgan TR, Ghany MG, HALT-C Trial Group. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology. 2011 Apr; 53 (4):1100-8. [Full Text/Abstract]
    Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Morgan TR, HALT-C Trial Group. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology. 2011 Mar; 140 (3):840-9; quiz e12. [Full Text/Abstract]
    Feld JJ, Modi AA, El-Diwany R, Rotman Y, Thomas E, Ahlenstiel G, Titerence R, Koh C, Cherepanov V, Heller T, Ghany MG, Park Y, Hoofnagle JH, Liang TJ. S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders. Gastroenterology. 2011 Mar; 140 (3):830-9. [Full Text/Abstract]
    Seeff LB, Ghany MG. Management of untreated and nonresponder patients with chronic hepatitis C. Semin Liver Dis. 2010 Nov; 30 (4):348-60. [Full Text/Abstract]
    Noureddin M, Ghany MG. Editorial: Treatment of patients with HCV-related cirrhosis with peginterferon and ribavirin: Swinging the pendulum toward treatment. Am J Gastroenterol. 2010 Oct; 105 (10):2174-6. [Full Text/Abstract]